Polypharmacy in Older Adults Undergoing Major Surgery: Prevalence, Association With Postoperative Cognitive Dysfunction and Potential Associated Anesthetic Agents

Saranya Lertkovit¹, Arunotai Siriussawakul¹,², Patumporn Suraarunsumrit³, Wanicha Lertpipopmetha⁴, Natapong Manomaivong⁵, Wittachi Wivatdechakul⁶ and Varalak Srinonprasert²,³*

¹ Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ² Faculty of Medicine Siriraj Hospital, Integrated Perioperative Geriatric Excellent Research Center, Mahidol University, Bangkok, Thailand, ³ Division of Geriatric Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁴ Department of Anatomy, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁵ Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, ⁶ Department of Orthopedics, Hatyai Hospital, Hat Yai, Thailand

Background: Polypharmacy, which is defined as the use of 5 or more medications, can exert significant adverse impact on older adult patients. The objective of this study was to determine the prevalence of polypharmacy, and to investigate its association with postoperative cognitive dysfunction (POCD) in older adult patients who underwent elective major surgery at Siriraj Hospital—Thailand’s largest national tertiary referral center.

Methods: This prospective study included older adult patients aged ≥65 years who were scheduled for elective major surgery during December, 2017 to December, 2019 study period. Patient demographic, sociodemographic, anthropometric, clinical, comorbidity, anesthetic, surgical, and medication data were collected and compared between the polypharmacy and non-polypharmacy groups. Postoperative cognitive dysfunction (POCD) was diagnosed in patients with at least a 2-point decrease in their Montreal Cognitive Assessment score after surgery. Multivariate logistic regression analysis was used to identify independent predictors of POCD.

Results: A total of 250 patients (141 males, 109 females) with an average age of 72.88 ± 6.93 years were included. The prevalence of polypharmacy was 74%. Preoperative data showed the polypharmacy group to be more likely to be receiving potentially inappropriate medications, to be scheduled for cardiovascular thoracic surgery, and to have more comorbidities. There was a non-significant trend in the association of polypharmacy and POCD (crude odds ratio [OR]: 2.11, 95% confidence interval [CI]: 0.90–4.94; p = 0.08). Benzodiazepine, desflurane, or isoflurane administration during surgery were all significantly associated with POCD in univariate analysis. Multivariate
INTRODUCTION

An aging society is defined as >10% of the population aged over 60 years, and an aged society is defined as more than 14% of the population aged over 60 years (1). Most high-income countries and many middle-income countries (including Thailand) have become aging countries. Increasing age is commonly associated with more comorbidities, multiple medications, and deterioration of organ function. Alterations of drug pharmacokinetics and pharmacodynamics among older adults increases the risk of adverse drug reactions, subsequent hospitalization, and increased mortality (2).

Polypharmacy is a global problem that is expected to worsen with advances in medicine and the increasing development and discovery of new drugs. There are several definitions of polypharmacy in the literature, and many studies that reported significant association between polypharmacy and subsequent negative clinical outcomes. The most commonly reported factors are taking five or more prescribed drugs and receiving potentially inappropriate medications (PIMs) (3–5). The likelihood of adverse drug reactions increases commensurate with the number of drugs taken, and rises in adverse drug reactions results in an increased number of hospital admissions (6). Polypharmacy exerts several other detrimental effects on older adults, including delirium and cognitive impairment, which increase medical expenses, morbidity, and mortality (7, 8). The risk increases if one or more prescriptions in a polypharmacy case are drugs defined as PIMs.

As the population ages, there is an increased incidence of anesthesia and surgery among older adults, and it has been established that age-related factors increase the likelihood of postoperative complications (9). Furthermore, polypharmacy was found in the majority of older adult patients undergoing major elective noncardiac surgery, and it was found to be associated with a reduced survival rate and a higher rate of adverse events (10).

Postoperative cognitive dysfunction (POCD) is defined as a decline in cognitive function after anesthesia and surgery. Symptoms of POCD may develop from within 1 week after surgery to months after surgery. In this setting, cognitive function includes learning and memory, verbal ability, perception, attention, executive function, and abstract thinking (11).

Meanwhile postoperative delirium (POD) is a sudden change in mental status marked by a disturbance of awareness of the environment and a disruption in attention after surgery. There are three types of POD expression: hypoactive, hyperactive, and mixed. POD may also be involved in the development of POCD. The difference between POD and POCD is that POD diagnosis involves symptom detection, whereas POCD diagnosis requires neuropsychological testing administered pre- and post-operatively. The prevalence of POCD was reported to be as high as 41% among older adult patients after some surgical procedures (12). Understanding the relationship among anesthesia, surgery, and cognitive impairment is essential for guiding clinical practice (13). Several potential causes of POCD have been proposed, including advanced age, prior delirium, preoperative cognitive impairment, low education, and the use of anticholinergic medications prior to surgery (14–18). Data specific to the association between POCD and medications used during the perioperative period are scarce. Previous study has addressed the issue of polypharmacy and cognitive decline, but not in postoperative setting (19). Accordingly, the aim of this study was to determine the prevalence of polypharmacy, and to investigate its association with POCD in older adult patients who underwent elective major surgery at Siriraj Hospital—Thailand’s largest national tertiary referral center.

METHODS

This prospective study was conducted as part of the Siriraj Integrated Perioperative Geriatric Research Network of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (study COA No. 515/2017). We recruited Thai-speaking patients who were aged 65 years or older and scheduled for elective major surgery during the December, 2017 to December, 2019 study period. Major surgery was defined as a procedure potentially lead to organ ischemia, high intraoperative blood loss, high noradrenalin requirements, long operative time, and requiring perioperative blood transfusion.
Operation generates systemic inflammatory response and the need for intermediate or intensive care was also considered as a major surgery. Potential consequences of major surgery include high morbidity and mortality (20). Patients unable to undergo cognitive assessments, having severe visual or auditory dysfunction, having significant psychotic disorders affecting their ability to cooperate, having preoperative delirium, or being bedridden were excluded. We also excluded patients who were unable to attend follow-up visits during the postoperative period. Patient baseline characteristics and intraoperative data were obtained from their electronic medical records.

Data Collection
Patient demographic data, comorbidities, body mass index (BMI), and current patient medication data were collected preoperatively via patient interview and review of hospital medical records. Intraoperative and postoperative data were also gathered from medical records, including type of surgery, anesthetic technique, anesthetic medications, operative time, and intraoperative and postoperative complications. Polypharmacy was defined as the use of five or more medications preoperatively (3). PIMs were identified according to Beers criteria (5) and assessment by a geriatrician. The Montreal Cognitive Assessment (MoCA)–Thai version was administered by a psychologist to measure each patient's baseline cognitive status before undergoing surgery. It evaluates at eight different cognitive abilities: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall, and orientation. The maximum MoCA score is 30, with a higher value indicating better performance. The test has been widely used to assess older people with various form of cognitive dysfunction.

During postoperative days 5–9, the same psychologist visited all enrolled participants at the inpatient ward. If they were medically stable (e.g., absence of acute stroke or hypotension), the MOCA test was readministered. POCD was diagnosed according to the previously published recommendation (21) that POCD be defined as a postoperative decrement of cognitive test scoring ≥ 1 standard deviation. However, in the present study, we diagnosed POCD when there was decrease of ≥2 points in the postoperative MoCA score compared to the preoperative MoCA score, which was also a previously reported diagnostic method (22).

Sample Size Calculation and Statistical Analysis
The sample size calculation took into account both components of our study objective. The primary objective of this study was to determine the prevalence of polypharmacy. Previous study reported a prevalence of polypharmacy of approximately 29% (23). Cochran's formula was used to calculate the sample size, with the Z value set to 1.96 at a 95% confidence level and the acceptable tolerance (e) set at 8%. Using those estimates, a minimum sample size of 116 patients would be required to satisfy the primary objective. Sample size calculation for secondary objective was also performed for identification of factors associated with POCD using multivariate analysis. We estimated following previous study which discovering 5 factors independently associated with the development of POCD (24). Using the rule of thumb method suggested for 10 events per variable with estimated prevalence of POCD of 20% from the Siriraj Integrated Perioperative Geriatric Research Network database, a minimum of 250 patients would be required. The final sample size for the study was therefore chosen to be 250.

All data analyses were performed using SPSS Statistics version 18 (SPSS, Inc., Chicago, IL, USA). Participant demographic, clinical, and intraoperative data were analyzed using descriptive statistics. We divided patients into two groups according to the number of medications they were taking, as follows: the polypharmacy group (five or more drugs) and the non-polypharmacy group (less than five drugs). Categorical data were compared using chi-square test or Fisher's exact test, and the results are given as number and percentage. Continuous data were compared using 2-sample t-test for normally distributed data (results shown as mean plus/minus standard deviation), and using Mann-Whitney U test for non-normally distributed data (results show as median and range; minimum, maximum). To identify association between polypharmacy and POCD, we

| Characteristics | (N = 250) |
|----------------|-----------|
| Age (years)    | 72.88 ± 6.93 |
| <70 years      | 75 (30.0%) |
| 70–79 years    | 130 (52.0%) |
| ≥80 years      | 45 (18.0%) |
| Education      |           |
| <12 years of education | 219 (88.7%) |
| ≥12 years of education | 28 (11.3%) |
| BMI            | 24.08 ± 4.10 |
| Underweight (<18.5 kg/m²) | 24 (9.6%) |
| Normal (18.5–24.9 kg/m²) | 131 (52.4%) |
| Overweight (25–29.9 kg/m²) | 75 (30.0%) |
| Obese (≥30.0 kg/m²) | 20 (8.0%) |
| ASA classification |   |
| II             | 60 (24.0%) |
| III            | 174 (69.6%) |
| IV             | 16 (6.4%) |
| Site of surgery |       |
| CVT            | 141 (56.4%) |
| Non-CVT        | 109 (43.6%) |
| Presence of polypharmacy | 185 (74%) |
| Presence of PIMs | 67 (26.8%) |

Data presented as mean ± standard deviation or number and percentage. SD, standard deviation; BMI, body mass index; ASA, American Society of Anesthesiology; CVT, cardiovascular thoracic surgery; PIMs, potentially inappropriate medications.
Lertkovit et al. Polypharmacy With Postoperative Cognitive Dysfunction

FIGURE 1 | The percentage of overall patients stratified by the number of drugs used. The results show the prevalence of polypharmacy (five or more drugs) to be 74% among older adults who underwent major surgery.

Results divided participants into groups based on the presence or absence of POCD. Evaluated variables with a $p < 0.10$ in univariate analysis were entered into multivariate analysis to identify factors that independently predict POCD. The results of the univariate and multivariate analyses are presented as crude and adjusted odds ratios (respectively) and their respective 95% confidence intervals. A $p < 0.05$ was considered statistically significant for all tests.

RESULTS

We evaluated 250 participants aged 65 and over who underwent elective major surgery. This study included 141 males and 109 females with an average age of 72.88 ± 6.93 years. Concerning the type of surgery, 141 patients underwent cardiovascular thoracic (CVT) surgery, and 109 had non-CVT surgery (Table 1). As demonstrated in Figure 1, polypharmacy was found in 74% ($n = 185$) of older adult patients who underwent surgery. Moreover, a 31% prevalence of PIMs was found in the polypharmacy group, which was significantly higher than the rate in the non-polypharmacy group (12.3%) ($p = 0.002$).

Patients in the polypharmacy group were significantly more likely to be scheduled for CVT surgery, to have higher disease burden (ASA Physical Status classification of three or above), and to have a higher prevalence of comorbidities, including hypertension, dyslipidemia, and ischemic heart disease/myocardial infarction. Antiarrhythmic drugs, antihypertensive drugs, diabetic drugs, diuretic drugs, and a benzodiazepine-based anxiety reliever were among the most common medications prescribed. In contrast, patients in the non-polypharmacy group had significantly more malignant cancer and alcohol use (Table 2). Carvedilol (26.4%), metformin (24.9%), furosemide (25.4%), amlodipine (23.7%), and enalapril (18.4%) were the first five most commonly prescribed drugs for patients in the polypharmacy group (Figure 2). Concerning anesthesia-related variables, which are shown in Table 3, patients with polypharmacy were significantly more likely to receive general anesthetic procedures (82.7%), inhalation (86.5%), isoflurane inhaler (35.1%), a muscle relaxant with rocuronium (42.2%), analgesic with morphine (55.1%), and blood transfusion (66.9%).

Regarding evaluation for POCD in this study. Only 175 patients were available for MoCA testing after surgery. Reason for data missing were unstable medical conditions death, unwillingness to answer questions, and discharging from the hospital prior to evaluation. Of those, 51 individuals (29.1%) were identified as having POCD. Table 4 shows variables potentially associated with POCD compared between the non-POCD and POCD groups. Ischemic heart disease/myocardial infarction, receiving antihypertensive drug, CVT surgery, received benzodiazepine during surgery, received isoflurane, received rocuronium muscle relaxant, and received blood product were all factors significantly associated with POCD. Having received desflurane and muscle relaxant reversal were both significantly more common among those found not to
TABLE 2 | Preoperative characteristics compared between the non-polypharmacy and polypharmacy groups.

| Characteristics               | Non-polypharmacy (n = 65) | Polypharmacy (n = 185) | p-value |
|------------------------------|---------------------------|------------------------|---------|
| Age                          | 73.32 ± 6.99              | 72.73 ± 6.92           | 0.557   |
| <70 years                    | 14 (21.5%)                | 61 (33.0%)             | 0.223   |
| 70–79 years                  | 38 (58.5%)                | 92 (49.7%)             |         |
| ≥80 years                    | 13 (20.0%)                | 32 (17.3%)             | 0.697   |
| Gender                       |                           |                        |         |
| Male                         | 38 (58.5%)                | 103 (55.7%)            |         |
| Female                       | 27 (41.5%)                | 82 (44.3%)             |         |
| Education                    |                           |                        | 0.424   |
| < 12 years of education      | 55 (85.9%)                | 164 (89.6%)            |         |
| ≥ 12 years of education      | 9 (14.1%)                 | 19 (10.4%)             |         |
| ASA classification           |                           |                        | <0.001* |
| II                           | 35 (53.8%)                | 25 (13.5%)             |         |
| III                          | 29 (44.6%)                | 145 (78.4%)            |         |
| IV                           | 1 (1.5%)                  | 15 (8.1%)              |         |
| Comorbidities                |                           |                        |         |
| Hypertension                 | 32 (49.2%)                | 167 (90.3%)            | <0.001* |
| Atrial fibrillation          | 7 (10.8%)                 | 25 (13.5%)             | 0.569   |
| Congestive heart failure     | 2 (3.1%)                  | 25 (13.5%)             | 0.020*  |
| Ischemic heart disease/myocardial infarction | 9 (13.8%) | 112 (60.5%) | <0.001* |
| Valvular heart disease       | 12 (18.5%)                | 46 (24.9%)             | 0.293   |
| Peripheral vascular disease  | 0 (0.0%)                  | 6 (3.2%)               | 0.344   |
| Dyslipidemia                 | 32 (49.2%)                | 138 (74.6%)            | <0.001* |
| Hyperthyroid                 | 1 (1.5%)                  | 2 (1.1%)               | 1.000   |
| Hypothyroid                  | 0 (0.0%)                  | 6 (3.2%)               | 0.344   |
| Diabetes mellitus            | 8 (12.3%)                 | 83 (44.9%)             | <0.001* |
| Asthma                       | 1 (1.5%)                  | 3 (1.6%)               | 1.000   |
| COPD                         | 2 (3.1%)                  | 3 (1.6%)               | 1.000   |
| CKD stage ≥3a                | 24 (36.9%)                | 82 (44.3%)             | 0.299   |
| Malignancy                   | 26 (40.0%)                | 40 (21.6%)             | 0.004*  |
| Cirrhosis                    | 1 (1.6%)                  | 5 (2.7%)               | 0.598   |
| Alcohol use                  | 5 (7.7%)                  | 4 (2.2%)               | 0.040*  |
| Current smoker               | 1 (1.5%)                  | 3 (1.6%)               | 1.000   |
| Medication group             |                           |                        |         |
| Antiarrhythmic drug          | 17 (26.2%)                | 109 (58.9%)            | <0.001* |
| Antidepressant drug          | 1 (1.5%)                  | 10 (5.4%)              | 0.297   |
| Antiemetic drug              | 0 (0.0%)                  | 5 (2.7%)               | 0.331   |
| Antihypertensive drug        | 39 (60.0%)                | 172 (93.0%)            | <0.001* |
| Benzodiazepine               | 3 (4.6%)                  | 41 (22.3%)             | <0.001* |
| Diabetic drug                | 4 (6.2%)                  | 67 (36.4%)             | <0.001* |
| Diuretic                     | 10 (15.4%)                | 58 (31.4%)             | 0.015*  |
| Site of surgery              |                           |                        | <0.001* |
| Non-CVT                      | 41 (63.1%)                | 68 (36.8%)             |         |
| CVT                          | 24 (36.9%)                | 117 (63.2%)            |         |
| Presence of PIMs             | 8 (12.3%)                 | 59 (31.9%)             | 0.002*  |

Data presented as mean ± standard deviation or number and percentage. A p < 0.05 indicates statistical significance. ASA, American Society of Anesthesiologists; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; CVT, cardiovascular thoracic surgery; PIMs, potentially inappropriate medications.

DISCUSSION

The prevalence of polypharmacy among older adult patients who underwent major surgery in this study was very high. This study also investigated for correlation between preoperative polypharmacy and POCD, which is a clinical setting for which data remain scarce. The results of this study showed only a trend toward significant association between polypharmacy and POCD (p = 0.08). Interestingly, we identified other medications that are commonly used intraoperatively to be both significantly and independently associated with POCD.

Polypharmacy is very common among older adults, which is a subpopulation that frequently has more chronic comorbidities.
that require a larger number of drugs to manage their illnesses (25, 26). However, the prevalence of polypharmacy is understudied and under-reported in the surgical setting. Recent studies have reported a prevalence of polypharmacy of 40–55% (9, 10, 27, 28). The negative consequences of polypharmacy in a postoperative setting have been variously reported (9, 10, 27, 28). Some studies found polypharmacy to be associated with poor postoperative outcomes, such as postoperative complications, functional decline, hospitalization, and increased mortality (10, 27); however, other studies did not report those results (9, 28). A prospective multicenter observational study (28) in older adults undergoing elective surgery found polypharmacy to be unrelated to the development of POCD. The present study found a very high 74% prevalence of polypharmacy, which is substantially higher than the rates reported in previous studies. Even though we found only a trend \( p = 0.08 \) toward significant association between polypharmacy and POCD among older adult patients who underwent elective major surgery, careful monitoring of older adults with polypharmacy should still be recommended in this setting.

POCD is a postoperative phenomenon that has been increasingly studied during the last decade. Although the exact pathology of POCD is unknown, it is thought to be caused by an inflammatory process in the brain. The systemic responses induced by anesthesia and surgery may trigger neuroinflammation and subsequent POCD. Many risk factors are thought to influence POCD onset, including increasing age, poor education, a history of cerebrovascular disease with no residual impairment, the duration and type of surgery, preexisting cognitive impairment, poor functional status, multiple comorbidities and severity of illness, and postoperative respiratory complications (29, 30). In line with the finding from other studies, older adults in the polypharmacy group have a greater percentage of comorbidities. However, consider from the Charlson’s comorbidity index between the POCD and non-POCD group, it appears that the complexity of comorbid diseases were not influence the occurrence of POCD in the present study.

Our multivariate analyses showed POCD to be independently associated with intraoperative benzodiazepine and isoflurane, which are anesthetic drugs, but not with other baseline risk factors. The association between anesthetics and cognitive impairment is of both interest and concern. Many medications used during anesthesia have systemic effects, with particular effects on cognitive abilities after surgery. However, the mechanism of anesthetics in POCD remains unknown, but several mechanisms have been proposed. Factors that may contribute to POCD include anesthetic approach, monitoring modality, and intraoperative complications. These factors influence modification of the tau protein, inflammation process, calcium dysregulation, and mitochondrial dysfunction, which have all been proposed to influence postoperative cognitive impairment (13).

Benzodiazepines are categorized as delirium-inducing medications (DIMs) (31, 32). This group of drugs is contraindicated in patients at high-risk for developing delirium (33). However, the studies in the relationship between benzodiazepine and POCD are few, and the results are conflicting. Li et al. (34) conducted a prospective randomized controlled trial of 164 older adult patients who underwent hip surgery.
### Table 3: Intraoperative data compared between the non-polypharmacy and polypharmacy groups.

| Data                                | Non-polypharmacy (n = 65) | Polypharmacy (n = 185) | p-value |
|-------------------------------------|---------------------------|------------------------|---------|
| Choice of anesthesia                |                           |                        | <0.001* |
| GA and RA                           | 17 (26.1%)                | 21 (11.4%)             |         |
| GA                                 | 36 (55.4%)                | 153 (82.7%)            |         |
| RA                                 | 12 (18.5%)                | 11 (6.9%)              |         |
| Special monitoring                  |                           |                        |         |
| BIS                                 | 2 (3.1%)                  | 5 (2.7%)               | 1.000   |
| NIRS                                | 4 (6.2%)                  | 11 (5.9%)              | 1.000   |
| Benzodiazepine use                  | 27 (41.5%)                | 102 (55.1%)            | 0.059   |
| Dexmedetomidine use                 | 9 (13.8%)                 | 19 (10.3%)             | 0.440   |
| Intraoperative adverse events       | 33 (51.6%)                | 75 (42.6%)             | 0.218   |
| Induction agents                    |                           |                        |         |
| Thiopental                          | 2 (3.1%)                  | 3 (1.6%)               | 0.607   |
| Propofol                            | 43 (66.2%)                | 141 (76.2%)            | 0.113   |
| Etomidate                           | 1 (1.5%)                  | 3 (1.6%)               | 1.000   |
| Propofol TCI                        | 7 (10.8%)                 | 14 (7.6%)              | 0.423   |
| Inhalation use                      |                           |                        | 0.004*  |
| No                                  | 19 (29.2%)                | 25 (13.5%)             |         |
| Yes                                 | 46 (70.8%)                | 160 (86.5%)            |         |
| Inhalation type                     |                           |                        |         |
| Desflurane                          | 13 (20.0%)                | 29 (15.8%)             | 0.422   |
| Sevoflurane                         | 25 (38.5%)                | 66 (35.9%)             | 0.688   |
| Isoflurane                          | 8 (12.3%)                 | 65 (35.1%)             | <0.001* |
| Muscle relaxant for intubation      |                           |                        |         |
| Pancuronium                         | 0 (0.0%)                  | 0 (0.0%)               | NA      |
| Atracurium                          | 13 (20.0%)                | 29 (15.7%)             | 0.422   |
| Cis-a-trcuronium                     | 25 (38.5%)                | 63 (34.1%)             | 0.522   |
| Succinylcholine                     | 2 (3.1%)                  | 1 (0.5%)               | 0.167   |
| Rocuronium                          | 13 (20.0%)                | 78 (42.2%)             | <0.001* |
| Analgesia used                      |                           |                        |         |
| Morphine                            | 18 (27.7%)                | 102 (55.1%)            | <0.001* |
| Pethidine                           | 1 (1.5%)                  | 2 (1.1%)               | 1.000   |
| Fentanyl                            | 59 (90.8%)                | 179 (96.8%)            | 0.084   |
| Ketamine                            | 0 (0.0%)                  | 3 (1.6%)               | 0.570   |
| COX-2 inhibitor                     | 1 (1.5%)                  | 2 (1.1%)               | 1.000   |
| Reversal agents used               | 30 (46.2%)                | 48 (26.4%)             | 0.003*  |
| Blood product used                  | 30 (46.2%)                | 121 (66.9%)            | 0.003*  |
| Other complications                 |                           |                        |         |
| Hypertension                        | 1 (1.6%)                  | 4 (2.2%)               | 1.000   |
| Hypotension                         | 29 (44.6%)                | 67 (37.0%)             | 0.302   |
| Hypotension2                        | 3 (4.7%)                  | 4 (2.2%)               | 0.382   |
| Severe arrhythmia                   | 9 (13.8%)                 | 29 (16.0%)             | 0.677   |
| Anesthetic time (min)               | 289 (40, 610)             | 282 (53, 775)          | 0.715   |

Data presented as number and percentage or mean ± standard deviation. A p < 0.05 indicates statistical significance.

### Table 4: Variables potentially associated with postoperative cognitive dysfunction (POCD) compared between the non-POCD and POCD groups.

| Variables                                 | Non-POCD (n = 124) | POCD (n = 51) | p-value |
|-------------------------------------------|--------------------|---------------|---------|
| Preoperative data                         |                     |               |         |
| Polypharmacy                              | 89 (71.8%)         | 43 (84.3%)    | 0.080   |
| PIMs                                      | 35 (27.4%)         | 14 (27.5%)    | 0.917   |
| Age (years)                               | 73.26 ± 6.46       | 71.10 ± 7.24  | 0.074   |
| Male gender                               | 69 (55.6%)         | 34 (66.7%)    | 0.178   |
| ASA Status                                | 0.061              |               |         |
| II                                         | 34 (27.4%)         | 5 (9.8%)      |         |
| III                                        | 85 (68.5%)         | 41 (80.4%)    |         |
| IV                                         | 5 (4.0%)           | 5 (9.8%)      |         |
| Comorbidity                               |                     |               |         |
| CCI ≤ 6                                   | 63 (50.8%)         | 25 (49.0)     |         |
| Ischemic heart disease/myocardial infarction | 51 (41.1%)     | 31 (60.8%)    | 0.018*  |
| Valvular heart disease                    | 25 (20.2%)         | 17 (33.3%)    | 0.064   |
| Preoperative medication                   |                     |               |         |
| Antiemetic drug                           | 2 (1.6%)           | 3 (5.9%)      | 0.513   |
| Antihypertensive drug                     | 99 (79.8%)         | 47 (92.2%)    | 0.046*  |
| Pre-benzodiazepine                        | 23 (18.5%)         | 10 (19.6%)    | 0.889   |
| Site of surgery                           |                     |               | <0.001* |
| Non-CVT                                   | 63 (50.8%)         | 12 (23.5%)    |         |
| CVT                                        | 61 (49.2%)         | 39 (76.5%)    |         |
| Intraoperative data                       |                     |               |         |
| Choice of anesthesia                      |                    |               | 0.022*  |
| GA and RA                                 | 22 (17.7%)         | 5 (9.8%)      |         |
| GA                                         | 86 (69.4%)         | 45 (88.2%)    |         |
| RA                                         | 16 (12.9%)         | 1 (2.0%)      |         |
| Benzodiazepine                            | 56 (45.2%)         | 36 (70.6%)    | 0.002*  |
| Inhalation use                            |                     |               | 0.442   |
| No                                        | 23 (18.5%)         | 7 (13.7%)     |         |
| Yes                                       | 101 (81.5%)        | 44 (86.3%)    |         |
| Inhalation type                           |                      |               |         |
| Desflurane                                | 24 (19.4%)         | 2 (3.9%)      | 0.009*  |
| Isoflurane                                | 29 (23.4%)         | 27 (52.9%)    | <0.001* |
| Muscle relaxant for intubution            |                     |               |         |
| Rocuronium                                | 40 (32.3%)         | 27 (52.9%)    | 0.011*  |
| Reversal agents used                      | 41 (33.6%)         | 9 (17.6%)     | 0.035*  |
| Received blood product                    | 70 (57.4%)         | 41 (80.4%)    | 0.004*  |
| Postoperative data                        |                     |               |         |
| Post-benzodiazepine                       |                   |               |         |

Data presented as number and percentage or mean ± standard deviation. A p < 0.05 indicates statistical significance.

POCD, postoperative cognitive dysfunction; PIMs, potentially inappropriate medications; ASA, American Society of Anesthesiologists; CVT, cardiovascular thoracic; GA, general anesthesia; RA, regional anesthesia; Pre-benzodiazepine, The patient was given benzodiazepine before the operation; Post-benzodiazepine, The patient was given benzodiazepine after the operation; CCI, Charlson comorbidity index. *p < 0.05.
TABLE 5 | Univariate analysis to identify factors that are potentially independently associated with postoperative cognitive dysfunction (POCD) in older adult patients after major surgery.

| Factors          | Non-POCD (n = 124) | POCD (n = 51) | Univariate analysis |
|------------------|---------------------|---------------|---------------------|
|                  | Crude OR (95% CI)   | p             |                     |
| Polypharmacy     | 2.11 (0.90–4.94)    | 0.084         |                     |
| Age              | 0.95 (0.90–1.00)    | 0.056         |                     |
| IHD/MI           | 2.21 (1.14–4.32)    | 0.019*        |                     |
|                             | Reference          |               |                     |
| Site of surgery   |                     |               |                     |
| Non-CVT          | 63 (50.8%)          | 12 (23.5%)    | 3.35 (1.60–7.01)    | <0.001*         |
| CVT              | 61 (49.2%)          | 39 (76.5%)    | 2.91 (1.44–5.88)    | 0.003*          |
| Benzodiazepine   | 56 (45.2%)          | 36 (70.6%)    | 0.17 (0.03–0.74)    | 0.019*          |
| Desflurane       | 24 (19.4%)          | 2 (3.9%)      | 3.68 (1.65–7.34)    | <0.001*         |
| Isoflurane       | 29 (23.4%)          | 27 (52.9%)    | 2.36 (1.21–4.60)    | 0.011*          |
| Rocuronium       | 40 (32.3%)          | 27 (52.9%)    | 0.42 (0.18–0.95)    | 0.038*          |
| Reversal agents  | 41 (33.6%)          | 9 (17.6%)     | 3.04 (1.39–6.63)    | 0.005*          |
| used             | 70 (57.4%)          | 41 (80.4%)    | 0.47–0.95           | 0.68            |

Factors with a p < 0.10 in univariate analysis will be entered into multivariate analyses. POCD, postoperative cognitive dysfunction; OR, odds ratio; CI, confidence interval; IHD/MI, ischemic heart disease/myocardial infarction; CVT, cardiovascular thoracic surgery.

A p < 0.05 indicates statistical significance. Multivariate backward stepwise logistic regression was analyzed separately for multicollinearity variables.

TABLE 6 | Multivariate analyses (models A and B) to identify independent predictors of postoperative cognitive dysfunction (POCD) in older adult patients after major surgery.

| Predictors                  | Model A (Included desflurane) | Model B (Included isoflurane) |
|-----------------------------|-------------------------------|-------------------------------|
|                             | Adjusted OR (95% CI)         | p-value          | Adjusted OR (95% CI)         | p-value          |
| Polypharmacy                | 1.91 (0.92–4.62)             | 0.048*          | 1.91 (0.92–4.62)             | 0.048*          |
| Benzodiazepine              | 2.27 (1.10–4.48)             | 0.011*          | 2.27 (1.10–4.48)             | 0.011*          |
| Desflurane                  | 0.21 (0.47–0.95)             | 0.066           | 0.21 (0.47–0.95)             | 0.066           |
| Isoflurane                  | –                             | –               | 2.80 (1.35–5.81)             | 0.006*          |

or knee replacement under spinal-epidural anesthesia (CSE) to assess the effects of dexmedetomidine, propofol, or midazolam sedation on POCD. They found that the group given midazolam had the highest prevalence of POCD. However, another study that was conducted by Mansouri et al. (35) in 150 candidates aged over 65 years who underwent cataract surgery under general anesthesia, which is thought to protect against cognitive function of older adults. Nevertheless, limited studies have been conducted in human that addressed the association between specific inhalation agent and the occurrence of POCD (13). Several studies in animal models demonstrated derangement in neurotransmitters and cytokines during isoflurane administration. Acharya et al. reported that isoflurane increased blood-brain barrier (BBB) permeability by destroying brain vascular endothelial cells in aging mice, which resulted in the secretion of various cytokines and proinflammatory mediators into the brain. This combined release caused abnormal brain function, and contributed to postoperative cognitive dysfunction (37). According to the findings of Cao et al., isoflurane induces inflammatory processes by secreting a significant quantity of proinflammatory cytokines, including tumor necrosis factor (TNF), interleukin 6 (IL-6), and interleukin 1 beta (IL-1β), which resulted in the deposition of a large amount of hypoxia-inducible factor 1-alpha (HIF-1α) protein at the hippocampus. They reported these findings to be associated with cognitive impairment (38). In the laboratory, Xie et al. (39) investigated H4 human neuroglioma cells that had been exposed to isoflurane. Their results showed increased amounts of β-amyloid protein and amyloid precursor protein (APP), which are both known to be associated with Alzheimer’s disease (AD). Another study in animals that was conducted by Liu et al. (40) found that isoflurane enhanced the development of Alzheimer’s disease (AD) (specific to spatial memory impairment) by increasing amyloid-beta (A-beta) levels and tau phosphorylation in the hippocampus of older rats. The accumulating evidence from animal studies suggests that isoflurane exposure in older adult population may be, in part, responsible for pathogenesis of POCD observed in the present study.

Desflurane is a volatile anesthetic drug with a low blood-gas partition coefficient that provides faster recovery following general anesthesia, which is thought to protect against cognitive
decline after anesthesia. The present study demonstrated a significant association effect of desflurane to reduce risk of POCD in univariate analysis; however, that significant effect was not sustained in multivariate analysis. It was reported that desflurane enhanced neurologic outcomes in patients who underwent cardiac bypass surgery, and in patients with hypoxic neuronal impairment (41). However, another study that investigated the effect of two volatile anesthetic drugs (desflurane and sevoflurane) on POCD reported no significant difference in the incidence of POCD between the two drugs (42). Given the mixed results from current and previous studies, further studies are needed to explore the effect of desflurane on POCD in older adult patients requiring anesthesia.

**Strengths and Limitations**

This study has several mentionable strengths and limitations. Regarding strengths, medication reconciliation is a routine practice in our center, so our determination of the medication used could be considered reliable. Second, this study was a prospective study designed to investigate for POCD, potential confounding factors and outcome were preplanned and therefore less likely to underestimate or misclassification. Concerning limitations, the first weakness of this study is that our data were derived from a single center, the generalizability might be limited and should preferable be further explored in other setting. Second, MoCA retesting was only performed in 175 patients out of 250 subjects initially included. This might lead to bias estimation of prevalence of POCD. However, we have compared baseline characteristics of those for whom MoCA was not repeated and discovered no statistical difference with the included group. We, therefore, hypothesize that the missing data would have minimal effect on the prevalence of POCD identified in the study. However, although the sample size was sufficient to investigate the prevalence of polypharmacy, it might not be adequate for exploring the association with POCD. Should the observed odd ratios of two from the association between polypharmacy and POCD be considered as clinically significant, it would require sample size around 400, estimated from the prevalence of polypharmacy. This study could have been underpowered to explore the association for polypharmacy and POCD. Furthermore, based on the finding of this study and a review of previous findings, it emerges that the effects of isoflurane and desflurane on POCD in humans are fascinating and could lead to changes in anesthetic practice. Further study with a larger sample size to explore the associations between those anesthetic agents, polypharmacy, and POCD is warranted.

**CONCLUSIONS**

The prevalence of polypharmacy in this study was a very high 74%. There was a non-significant trend toward ($p = 0.08$) increased risk of POCD in the polypharmacy group. Intraoperative benzodiazepine and isoflurane were identified as independent predictors of POCD, whereas desflurane was found to be an independent protective factor against POCD. Since POCD can significantly adversely impact older adult patients and their families, strategies to manage these modifiable factors are needed to improve patient outcomes.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The protocol for this study was approved by the Institutional Review Board of the Human Research Protection Unit, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (COA No. Si 189/2019). The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the
individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

SL, WL, NM, WW, AS, and VS contributed to the study’s conception and design. SL, AS, PS, and VS were responsible for data collection and analysis. SL, WL, AS, and VS interpreted the data and prepared the manuscript. All authors read and approved the final manuscript.

**REFERENCES**

1. Estebsari F, Dastoorpoor M, Khalifehkandi ZR, Nouri A, Mostafaei D, Hosseini M, et al. The concept of successful aging: a review article. *Carr Aging Sci.* (2020) 134–10. doi: 10.2174/187469012666191023130117
2. Karlamangla A, Tinetti M, Guralnik J, Studenski S, Wle T, Reuben D. Comorbidity in older adults: nosology of impairment, diseases, and conditions. *J Gerontol A Biol Sci Med Sci.* (2007) 62:296–300. doi: 10.1093/gerona/62.3.296
3. Masnoon N, Shabk S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. *BMC Geriatrics.* (2017) 17:230. doi: 10.1186/s12877-017-0621-2
4. Kim J, Parish AL. Polypharmacy and medication management in older adults. *Nurs Clin North Am.* (2017) 52:457–68. doi: 10.1016/j.cnur.2017.04.007
5. By the American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. *J Am Geriatr Soc.* (2019) 67:674–94. doi: 10.1111/jgs.15767
6. Lim B-G, Lee I-O. Anesthetic management of geriatric patients. *Korean J Anesthesiol.* (2020) 73:78–39. doi: 10.4097/kja.19391
7. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. *Expert Opin Drug Saf.* (2014) 13:57–65. doi: 10.15171/14740338.2013.827660
8. Ruangritchankul S. Polypharmacy in the Elderly. *Rama Med J.* (2018) 41:95–104. doi: 10.14456/rmj.2018.9
9. Choi KS, Yoon YM, Lee E, Kim KL, Yee J, Lee BK, et al. Association of pre-operative medication use with post-surgery mortality and morbidity in oncology patients receiving comprehensive geriatric assessment. *Aging Clin Exp Res.* (2018) 30:1177–85. doi: 10.1007/s40520-018-0909-2
10. McIsaac DI, Wong CA, Bryson GL, van Walraven C. Association of polypharmacy with survival, complications, and healthcare resource use after elective noncardiac surgery: a population-based cohort study. *Anesthesiology.* (2018) 128:1140–50. doi: 10.1097/ALN.0000000000002124
11. Deiner S, Silverstein JH. Postoperative delirium and cognitive dysfunction. *Clinics Brasil J of Anesthesia.* (2009) 103:41–16. doi: 10.1016/j.bjaesp.291
12. Monk TG, Weldon BC, Garvan CW, Dede DE, van der Aa MT, Heilman KM, et al. Predictors of cognitive dysfunction after major noncardiac surgery. *Anesthesiology.* (2008) 108:18–30. doi: 10.1097/01.ane.0000296071.19434.e1
13. Belrose JC, Noppens RR. Anesthesiology and cognitive impairment: a narrative review of current clinical literature. *BMC Anesthesiol.* (2019) 19:241. doi: 10.1186/s12871-019-0093-7
14. Canet J, Raeder J, Rasmussen LS, Elmund L, Kuipers HM, Hanning CD, et al. Cognitive dysfunction after minor surgery in the elderly. *Acta Anaesthesiol Scand.* (2003) 47:1204–10. doi: 10.1034/j.1399-6576.2003.00238.x
15. Wacker P, Nunes PV, Cabrita H, Forlenza OV. Post-operative delirium is associated with poor cognitive outcome and dementia. *Dement Geriatr Cogn Disord.* (2006) 21:211–7. doi: 10.1159/000091022
16. Rudolph JL, Marcantonio ER, Culley DJ, Silverstein JH, Rasmussen LS, Crosby GJ, et al. Delirium is associated with early postoperative cognitive dysfunction. *Anaesthesia.* (2008) 63:941–7. doi: 10.1111/j.1365-2044.2008.05523.x
17. Gruber-Baldini AL, Zimmerman S, Morrison RS, Grattan LM, Hebel JR, Dolan MM, et al. Cognitive impairment in hip fracture patients: timing of detection and longitudinal follow-up. *J Am Geriatr Soc.* (2003) 51:1227–36. doi: 10.1046/j.1532-5415.2003.51100.x
18. Feinhold I, Wintzerer G, Spies CD, Pschom T. Cognitive reserve and the risk of postoperative cognitive dysfunction. *Dtsch Arztebl Int.* (2017) 114:110–7. doi: 10.3238/arztebl.2017.0110
19. Oyarzun-Gonzalez XA, Taylor KC, Myers SR, Muldoon SB, Baumgartner RN. Cognitive decline and polypharmacy in an elderly population. *J Am Geriatr Soc.* (2015) 63:397–9. doi: 10.1111/jgs.12383
20. Martin D, Mantziari S, Demartines N, Houben M, Group ESAS. Defining major surgery: a delphi consensus among European Surgical Association (ESA) members. *World J Surg.* (2020) 44:2211–9. doi: 10.1007/s00268-020-05476-4
21. Evered L, Silbert B, Knopman DS, Scott DA, DeKosky ST, Rasmussen LS, et al. Recommendations for the Nomenclature of Cognitive Change Associated with Anesthesia and Surgery-2018. *Anesthesiology.* (2018) 129:872–9. doi: 10.1097/ALN.0000000000002534
22. Tangwongchai S PM, Charernboon T, Akkayagorn L, Hemmunrojng S, Phanthumchinda K, Nasredeena ZA. The validity of thai version of the montréal cognitive assessment (MoCA-T). *Dement Neuropsychol.* (2009) 3:172.
23. Wongpakaran N, Wongpakaran T, Sirirak T, Jenraumjit R, Jiriramnai S, Lerttrakarnnon P. Predictors of polypharmacy among elderly Thais with depressive and anxiety disorders: findings from the DAS study. *BMC Geriatr.* (2018) 18:309. doi: 10.1186/s12877-018-1001-2
24. Rundhagen I. Postoperative cognitive dysfunction. *Dtsch Arztebl Int.* (2014) 111:19–25. doi: 10.3238/arztebl.2014.0119
25. Zhang N, Sundquist J, Sundquist K, Ji J. An increasing trend in the prevalence of polypharmacy in Sweden: a nationwide register-based study. *Front Pharmacol.* (2020) 11:326. doi: 10.3389/fphar.2020.00326
26. Morin L, Johnell K, Laroche M-L, Fastbom J, Wastesson JW. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. *Clin Epidemiol.* (2018) 10:289–98. PubMed PMID: 29559811. doi: 10.2147/CLEP.S153458
27. Abe N, Kamaku T, Kumagai T, Hidaka T, Masuishi Y, Endo S, et al. Polypharmacy at admission prolongs length of hospitalization in gastrointestinal surgery patients. *Geriatr Gerontol Int.* (2020) 20:1085–90. doi: 10.1111/ggi.14044
28. Heinrich M, Notthbrook A, Borchers F, Morgen R, Kruppa J, Winterer G, et al. Polypharmacy and postoperative delirium and cognitive dysfunction. *Clin Transl Sci.* 14:1830–40. doi: 10.1111/cts.13031
29. Needham MJ, Webb CE, Bryden DC. Postoperative cognitive dysfunction and dementia: what we need to know and do. *Br J Anaesth.* (2017) 119:115–25. doi: 10.1093/bja/aex354
30. Li D, Liu H. Cognitive function assessment should be included in preoperative evaluation. *J Biomed Res.* (2017). 32:161–3. doi: 10.7555/JBR.32.20180008
31. Alagiakrishnan K, Wiens CA. An approach to drug induced delirium in the elderly. *Postgrad Med J.* (2004) 80:388–93. doi: 10.1136/pgmj.2003.017236
32. Jeong YM, Lee E, Kim KI, Chung JE, In Park H, Lee BK, et al. Association of pre-operative medication use with post-operative delirium...
in surgical oncology patients receiving comprehensive geriatric assessment. 

33. Clegg A, Young JB. Which medications to avoid in people at risk of delirium: a systematic review. Age Ageing. (2011) 40:23–9. doi: 10.1093/ageing/afr140

34. Li WX, Luo RY, Chen C, Li X, Ao JS, Liu Y, et al. Effects of propofol, dexmedetomidine, and midazolam on postoperative cognitive dysfunction in elderly patients: a randomized controlled preliminary trial. Clin Med J (Engl). (2019) 132:437–45. doi: 10.1097/CM9.0000000000000998

35. Mansouri N, Nasrollahi K, Shetabi H. Prevention of cognitive dysfunction after cataract surgery with intravenous administration of midazolam and dexmedetomidine in elderly patients undergoing cataract surgery. Adv Biomed Res. (2019) 8:6. doi: 10.4103/abr.abr_190_18

36. Kok L, Slooter AJ, Hillegers MH, van Dijk D, Veldhuijzen DS. Benzodiazepine use and neuropsychiatric outcomes in the ICU: A systematic review. Crit Care Med. (2018) 46:1673–80. doi: 10.1097/CCM.0000000000003300

37. Acharya NK, Goldwaser EL, Forsberg MM, Godsey GA, Johnson CA, Sarkar A, et al. Sevoflurane and Isoflurane induce structural changes in brain vascular endothelial cells and increase blood-brain barrier permeability: Possible link to postoperative delirium and cognitive decline. Brain Res. (2015) 1620:29–41. doi: 10.1016/j.brainres.2015.04.054

38. Cao Y, Li Z, Ma L, Ni C, Li L, Yang N, et al. Isoflurane-induced postoperative cognitive dysfunction is mediated by hypoxiainducible factor α dependent neuroinflammation in aged rats. Mol Med Rep. (2018) 17:7730–6. doi: 10.3892/mmr.2018.8850

39. Xie Z, Dong Y, Maeda U, Alfield P, Culley Deborah J, Crosby G, et al. The common inhalation anesthetic isoflurane induces apoptosis and increases amyloid β protein levels. Anesthiology. (2006) 104:988–94. doi: 10.1097/00000542-200605000-00015

40. Liu W, Xu J, Wang H, Xu C, Ji C, Wang Y, et al. Isoflurane-induced spatial memory impairment by a mechanism independent of amyloid-beta levels and tau protein phosphorylation changes in aged rats. Neurol Res. (2012) 34:3–10. doi: 10.11179/1743132811Y.000000047

41. Tachibana S, Hayase T, Osuda M, Kazuma S, Yamakage M. Recovery of postoperative cognitive function in elderly patients after a long duration of desflurane anesthesia: a pilot study. J Anesth. (2015) 29:627–30. doi: 10.1007/s00540-015-1979-y

42. Alawati R, Yasmeen N. Postoperative cognitive dysfunction in the elderly: a review comparing the effects of desflurane and sevflurane. J Perianesth Nurs. (2018) 33:732–40. doi: 10.1016/j.jopan.2017.04.009

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Lertkovit, Siriussawakul, Suraarunsumrit, Lertpipopmetha, Manomaiwong, Wivatdechakul and Srinonprasert. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.